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The N-terminal residue influences protein stability through N-degron pathways. 
Here, through stability profiling of the human N-terminome, we uncover multiple 
additional features of N-degron pathways. In addition to uncovering extended 
specificities of UBR E3 ligases, we characterized two related Cullin-RING E3 ligase 
complexes, Cul2ZYG11B and Cul2ZER1, that act redundantly to target N-terminal glycine. 
N-terminal glycine degrons are depleted at native N-termini but strongly enriched at 
caspase cleavage sites, suggesting roles for the substrate adaptors ZYG11B and ZER1 in 
protein degradation during apoptosis. Furthermore, ZYG11B and ZER1 participate in 
the quality control of N-myristoylated proteins, wherein N-terminal glycine degrons are 
conditionally exposed following a failure of N-myristoylation. Thus, an additional N-
degron pathway specific for glycine regulates the stability of metazoan proteomes. 
 
 
One Sentence Summary: 
Stability profiling of the human N-terminome uncovers an N-degron pathway through 








The ubiquitin-proteasome system (UPS) is the major route through which eukaryotic cells 
achieve selective protein degradation (1). The specificity of this system is provided by E3 
ubiquitin ligases, of which more than 600 are encoded in the human genome. E3 ligases 
recognize specific sequence elements, known as degrons, that are present in substrate proteins 
(2). However, whilst a detailed knowledge of the specificity of E3 ligases for degrons will be 
essential for achieving a systems-level understanding of the UPS, our current knowledge of 
degron motifs remains remarkably sparse (3). 
The first degrons to be discovered were located at the N-terminus of proteins (4). N-
terminal degrons are targeted by N-degron pathways (formerly known as N-end rule 
pathways (5)), of which there are two main branches: the Arg/N-degron pathway, through 
which UBR-family E3 ligases target N-termini typically generated through endoproteolytic 
cleavage (6, 7), and the Ac/N-degron pathway, through which proteins bearing acetylated N-
termini are targeted for degradation by the E3 ligase MARCH6 (also known as TEB4) (8, 9). 
In addition, a Pro/N-degron pathway was recently described, through which proteins 
harboring an N-terminal proline residue are degraded by the GID E3 ligase complex (10) (fig. 
S1). Theoretically these pathways have the capacity to target the majority of cellular proteins, 
but the extent to which they impact protein stability in a physiological context remains 
unclear. For example, loss of N-terminal acetyltransferase (NAT) enzymes has minimal 
effects on protein stability in yeast (11), which is inconsistent with a widespread role for the 
Ac/N-degron pathway.  
Previously we modified the Global Protein Stability (GPS) system (12) to develop a 
high-throughput method to characterize degron motifs in human proteins (13). This approach 
is based on a lentiviral expression vector encoding two fluorescent proteins: DsRed, which 
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serves as an internal reference, and GFP fused to a short peptide of interest, which is 
translated from an internal ribosome entry site (IRES). Because both DsRed and the GFP-
peptide fusion protein are expressed from the same transcript, the GFP/DsRed ratio can be 
used to quantify the effect of the peptide sequence on the stability of GFP (13). Here, we 
exploit the ubiquitin-fusion technique (4) to adapt this “GPS-peptidome” approach to search 
for N-terminal degron motifs. We thereby directly examined the contribution of N-terminal 
sequences to protein stability in human cells. 
 
Stability profiling of the human N-terminome using GPS-peptidome technology 
We synthesized an oligonucleotide library encoding the first 24 amino acids of the 
primary isoform(s) of all human proteins, both with and without an initiator methionine 
(~50,000 sequences). These were cloned into the “Ub-GPS” expression vector between the 
ubiquitin gene and GFP (Fig. 1A). Upon expression of the constructs in HEK-293T cells, 
proteolytic cleavage of the ubiquitin moiety by endogenous deubiquitinating enzymes led to 
the exposure of the peptides at the N-terminus of GFP (Fig. 1A). Fluorescence-activated cell 
sorting (FACS) was used to partition the population into six bins of equal size based on the 
stability of the peptide-GFP fusion. The stability of each fusion was then quantified by 
Illumina sequencing, with each peptide assigned a protein stability index (PSI) score ranging 
between 1 (maximally unstable) and 6 (maximally stable) based on the proportion of 
sequencing reads in each bin (data S1). 
We began by assessing the effect of the initiator methionine on protein stability. 
Overall, peptide-GFP fusions lacking an initiator methionine were much less stable than their 
counterparts with an initiator methionine (Fig. 1B). However, this effect was only observed 
for certain N-terminal residues (Fig. 1C). Reporters commencing with amino acids bearing 
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small side chains (C, V, G, P, T, A and S) were generally relatively stable, and exhibited little 
or no difference in overall stability whether or not they were preceded by an upstream 
methionine residue. This is consistent with efficient cleavage of the initiator methionine by 
methionine aminopeptidases when the following amino acid has a sufficiently small radius of 
gyration (14). In contrast, peptide-GFP fusions commencing with all other residues (except 
methionine itself) were generally stable only when preceded by an upstream methionine 
residue, and were greatly destabilized in the absence of an initiator methionine (Fig. 1C-F).  
Overall, these data provide strong support for a central role of the Arg/N-degron 
pathway in protein quality control. Whereas proteins bearing native N-termini (methionine 
itself, or C/V/G/P/T/A/S, from which methionine is normally removed (14)) are broadly 
stable, proteins bearing aberrant N-termini (R/K/H/W/Y/F/L/I/D/E/N/Q, without a preceding 
methionine) are all highly unstable. The latter residues correspond perfectly to the primary 
type I (R/K/H), primary type II (W/Y/F/L/I), secondary (D/E) and tertiary (N/Q) N-terminal 
degrons of the Arg/N-degron pathway (fig. S1A). Crucially, however, when these residues 
were preceded by methionine – as they would be in the context of normal protein synthesis – 
broad stabilization was observed (Fig. 1F).  
 
Computational identification of destabilizing N-terminal motifs 
Subsequently we focused on understanding the factors that determined the stability of 
peptide-GFP fusions synthesized with an initiator methionine. Stability scores for these 
fusions were distributed bimodally, with approximately one-third of the library exhibiting 
significant instability (Fig. 1B, blue histogram). One key factor that strongly influenced 
stability was amino acid composition (Fig. 2, A and B). For example, aspartic acid and 
glutamic acid were depleted from unstable peptides and enriched among the stable peptides, 
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while hydrophobic residues such as tryptophan, phenylalanine and leucine showed the 
opposite pattern. This effect is not specific to the N-terminus, however, as we find that 
similar rules govern the stability of reporter constructs in which peptides are fused at the C-
terminus of GFP (13).  
Most amino acids exerted a similar effect on stability regardless of their position 
across the 24-mer peptide, but we noticed that certain residues exerted differing effects 
specifically when encoded at the second position (Fig. 2, A and B). We therefore performed 
a computational analysis to identify motifs that might promote instability specifically when 
located at or near the N-terminus of the peptide. For all possible combinations of di-peptide 
motifs, we compared the mean stability of all peptide-GFP fusions harboring the motif within 
the first seven N-terminal amino acids versus those harboring the motif at an internal position 
in the 24-mer peptide (Fig. 2C and data S2). Over 80% of the top 100 candidate 
destabilizing N-terminal motifs could be grouped into four categories based solely on the 
identity of the second residue: lysine was present downstream of the initiator methionine in 
26 motifs, arginine in 24 motifs, glycine in 22 motifs and cysteine in 9 motifs (Fig. 2D). 
Reporters encoding these residues at the second position were significantly less stable than 
reporters containing these residues at any internal position (Fig. 2E), and, globally, peptide-
GFP fusions commencing MC-, MR-, MG- and MK- exhibited the lowest mean stability 
(Fig. 2F). Thus, considering initiator methionine removal, this analysis identified N-terminal 
glycine and cysteine in addition to MR- and MK- as candidate destabilizing N-terminal 
motifs. 
 
Exploring the substrate repertoire of UBR family E3 ligases 
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Next we sought to identify the cellular machinery targeting each class of putative N-
terminal degron. We began by investigating a role for UBR family E3 ligases. UBR1, UBR2 
and UBR4 have been shown functionally to participate in the recognition of N-degrons (15), 
and so, through sequential rounds of CRISPR/Cas9-mediated gene disruption, we attempted 
to create a single cell clone lacking all three of these UBR proteins. Despite screening ~40 
clones, we were unable to identify a clone in which simultaneous ablation of UBR1, UBR2 
and UBR4 proteins was observed by immunoblot, suggesting that such a triple mutant cell 
may not be viable. However, we were able to generate clones expressing substantially 
reduced levels of two or more of the proteins (Fig. 3A). Ub-GPS reporters in which the 
initiator methionine of GFP was replaced with either arginine (R), lysine (K) or tyrosine (Y) 
were strongly destabilized in wild-type cells, but this effect was abrogated in UBR KO clone 
#1 and clone #3 (fig. S2A) and completely abolished in clone #2 (Fig. 3B).  
We created a panel of Ub-GPS constructs in which either 23-mer peptides (Fig. 2C) 
or 3-mer peptides (fig. S2B) harboring example degron motifs downstream of an initiator 
methionine were fused to the N-terminus of GFP. In both cases, loss of UBR proteins 
resulted in the stabilization of reporters bearing three of the classes of degrons motifs: MK-, 
MR- and N-terminal cysteine. However, loss of UBR proteins had little or no effect on the 
stability of the GFP-fusion proteins bearing N-terminal glycine, suggesting a role for 
additional E3 ligase(s) in the recognition of this particular N-terminal degron. 
It was not surprising that UBR E3 ligases targeted N-terminal cysteine, given that 
nitric oxide-mediated oxidation and subsequent arginylation of N-terminal cysteine renders it 
a substrate for the Arg/N-degron pathway (16). That said, ATE1 disruption only led to 
modest stabilization of two peptide-GFP substrates exposing N-terminal cysteine (fig. S2, C 
and D), suggesting that additional routes to UBR-mediated degradation must also exist. 
UBR-mediated degradation of proteins commencing MK- and MR- was unexpected, 
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however, suggesting that, in addition to targeting truncated proteins bearing abnormal N-
termini, UBR ligases might also target certain intact proteins bearing their initiator 
methionine. To confirm that the initiator methionine of these substrates was indeed intact, 
and thus rule out the possibility that methionine removal was instead exposing canonical 
Arg/N-degrons, we used mass spectrometry to examine the N-terminus of two example 
peptide-GFP UBR substrates expressed in UBR KO clone #2 (fig. S3A). In both cases we 
were readily able to detect the intact N-terminal peptide with the initiator methionine present, 
while we could not detect any peptides corresponding to a putative processed form without an 
initiator methionine (fig. S3B). 
To further examine this property of UBR proteins, we directly compared the stability 
of the entire Ub-GPS N-terminome library in wild-type cells versus UBR KO clones #1, #2 
and #3 (Fig. 3D and data S3A). Loss of UBR proteins had little effect on the overall stability 
of reporters synthesized with an N-terminal methionine: only 570 peptide-GFP fusion 
proteins (<3% of the N-terminome library) exhibited substantial stabilization (>0.8 PSI units) 
in any of the UBR mutant clones compared to control cells (Fig. 3E). Sequence analysis of 
the UBR substrates revealed a clear preference for particular N-terminal degron motifs (Fig. 
3F and fig. S4A-H). Consistent with our previous data (Fig. 2C and fig. S2B), peptides 
commencing MC-, MK- and MR- were all enriched. Peptides commencing ML- and MI- 
were also overrepresented, and for three example peptides in each case we validated that they 
were indeed stabilized in UBR KO clone #2 (fig. S4I). In S. cerevisiae Ubr1 has been shown 
to target proteins commencing MΦ- (where Φ is a bulky hydrophobic residue, W/F/Y/L/I) for 
degradation (17); however, unlike peptides starting ML- and MI-, we did not observe 
enrichment for peptides starting MF- or MY- among the UBR substrates, and only weak 
enrichment for peptides starting MW-.  
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Finally, we noted that only a small proportion of all peptides in the library 
commencing MK-, MR-, ML- or MI- were UBR substrates, suggesting that additional 
residues were essential for degron recognition. Indeed, analysis of the composition of all the 
UBR substrates identified in each category highlighted preferred residues enriched at 
downstream positions (fig. S4E-H). Furthermore, for some example peptides starting MK-, 
MR- and MC- we defined the N-terminal UBR degron in detail by performing saturation 
mutagenesis experiments. We created a Ub-GPS library in which each of the residues from 
position 2 to position 10 of the 24-mer peptide were mutated to all other possible amino 
acids, and measured the stability of the resulting peptide-GFP fusions by FACS and Illumina 
sequencing (data S4A). These experiments confirmed the critical importance of the lysine, 
arginine or cysteine residue encoded at the second position, but also demonstrated that certain 
mutations at the third or fourth position could prevent degron recognition (Fig. 3G-I and fig. 
S5). These data also confirmed the requirement for these degron motifs to be positioned at the 
extreme N-terminus, as addition of just a single upstream amino acid (that is, immediately 
after the initiator methionine) resulted in stabilization of the peptide-GFP fusions (Fig. 3G-I 
and fig. S5, column labeled ‘add’).  
 
N-terminal glycine can act as a potent degron 
 We next focused on the one class of N-terminal degron motif that was not a substrate 
for UBR-mediated degradation: N-terminal glycine. To validate that N-terminal glycine did 
indeed constitute a degron motif, we performed a series of mutagenesis experiments on a 
panel of unstable Ub-GPS reporters in which 24-mer peptides commencing MG- were fused 
to the N-terminus of GFP (Fig. 4A and fig. S6A). In each case the glycine residue was 
indeed critical for instability, as a single substitution converting the glycine residue to serine 
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(G2S) was sufficient to inhibit degradation (Fig. 4A and fig. S6A, left). Moreover, the 
position of the glycine residue at the extreme N-terminus was also critical, as addition of a 
single serine residue upstream of the glycine (add S) stabilized the peptide-GFP fusions to a 
similar extent (Fig. 4A and fig. S6A, center). Finally, consistent with the notion that the 
initiator methionine is constitutively cleaved when followed by a small residue such as 
glycine, deletion of the initiator methionine (ΔMet) had no stabilizing effect on any of the 
peptide-GFP fusions (Fig. 4A and fig. S6A, right). 
 For some example peptides we defined the N-terminal glycine degron in detail by 
performing saturation mutagenesis experiments (data S4A). This confirmed the absolute 
requirement for the exposure of glycine at the extreme N-terminus, as addition of any single 
amino acid upstream of the glycine resulted in stabilization of the peptide-GFP fusion (Fig. 
4B and fig. S6B-G, column labeled ‘add’). The size of the degron motif appeared to be 
relatively small, but some substitutions at the residues immediately downstream of the 
exposed glycine did exert a stabilizing effect (Fig. 4B and fig. S6B-G).  
 
Cul2ZYG11B and Cul2ZER1 target N-terminal glycine 
 We began the search for the E3 ligase(s) responsible for targeting N-terminal glycine 
by using the small molecule MLN4924. MLN4924 acts as a broad inhibitor of Cullin-RING 
ligases (CRLs) by blocking Cullin neddylation (18), thus allowing us to narrow the search to 
either CRL or non-CRL ligase families. All our example Ub-GPS constructs bearing N-
terminal glycine were stabilized upon treatment with MLN4924, implicating CRLs in the 
recognition of N-terminal glycine (Fig. 4C and fig. S7A). 
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Next we sought to identify the specific CRL adaptor(s) responsible for recognition of the N-
terminal glycine degron. Employing dominant-negative constructs to inhibit each of the 
major Cullins, we determined that either Cul2 or Cul5 was responsible for the degradation of 
example Ub-GPS reporters harboring N-terminal glycine degrons (Fig. 4D and fig. S7B). 
Using these reporter substrates, we performed a series of CRISPR/Cas9-mediated genetic 
screens using a library of single guide RNAs (sgRNAs) targeting known CRL2/5 substrate 
adaptor proteins (fig. S8A). Together these screens identified ZYG11B as the CRL2 substrate 
adaptor responsible for recognition of the N-terminal glycine degron motif (Fig. 4E, fig. S8B 
and data S5). Intriguingly, ZER1, which is closely related to ZYG11B (29% amino acid 
identity) (fig. S8C), was enriched at or approaching the level of statistical significance in 
several screens, suggesting that these two related adaptors may collaborate in the degradation 
of proteins exposing N-terminal glycine (Fig. 4F). The third member of the ZYG11 family, 
ZYG11A, did not score in any of the screens, consistent with RNA-seq data (19) suggesting 
that it is rarely expressed across human tissues (fig. S8, C and D).  
To examine the possibility of cooperation between ZYG11B and ZER1, we 
performed individual CRISPR/Cas9-mediated gene disruption experiments, ablating the 
function of ZYG11B or ZER1 either alone or in combination. Loss of ZYG11B alone did 
indeed stabilize all of the peptide-GFP fusion proteins (Fig. 4G and fig. S9A), but, whilst 
complete stabilization was observed for two of the reporters (fig. S9A), only partial 
stabilization was observed for the others. In contrast, loss of ZER1 alone had little stabilizing 
effect on any of the reporters; however, simultaneous disruption of both ZER1 and ZYG11B 
resulted in complete stabilization (Fig. 4G and fig. S9A). Furthermore, ZYG11B and ZER1 
both associated with putative substrates bearing N-terminal glycine degrons (fig. S9B), and 
exogenous expression of either ZYG11B or ZER1 alone in ZYG11B/ZER1 double mutant 
cells fully restored the degradation of a peptide-GFP fusion whose stabilization required 
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ablation of both endogenous ZYG11B and ZER1 (Fig. 4H). Finally, we validated that 
Cul2ZYG11B and Cul2ZER1 were able to mediate the degradation of full-length proteins bearing 
exposed glycine residues at their N-termini (Fig. 4, I and J and fig. S9C-E).  
To obtain a global view of the substrates targeted by these Cul2 complexes, we 
compared the stability of the Ub-GPS N-terminome library in wild-type cells versus cells 
lacking either ZYG11B, ZER1 or both ZYG11B and ZER1 (fig. S10A and data S3B). First, 
this revealed that ZYG11B and ZER1 share the majority of their substrates: there were 115 
fusions stabilized in ZYG11B mutant cells and 36 stabilized in ZER1 mutant cells, while 488 
were stabilized in the double mutant cells. Sequence analysis of these shared substrates 
confirmed that N-terminal glycine was the most enriched feature, whilst also highlighting 
preferred (F, G, H, K and Y) and disfavored (D, E, I, P, S and T) residues at the following 
position (fig. S10B). Of the substrates that were targeted solely by ZYG11B, over 90% 
encoded a glycine residue at the second position (fig. S10C). Intriguingly, there was no 
enrichment of N-terminal glycine among the substrates exclusively targeted by ZER1 (fig. 
S10D). This finding suggested that (1) any ZER1 substrates bearing an N-terminal glycine 
were also substrates for ZYG11B, and hence were still targeted for degradation in ZER1 
mutant cells, and (2) whilst N-terminal glycine was indispensable for recognition by 
ZYG11B, in some contexts ZER1 might recognize substrates commencing with residues 
other than glycine. We characterized one such substrate – the N-terminal peptide derived 
from KCNT2 (commencing MPYL) - in detail (fig. S11). In particular, saturation 
mutagenesis revealed that the hydrophobic residues encoded at the third and fourth position 
formed a critical part of the ZER1 degron, while some more flexibility was tolerated at the 
second position (fig. S11G). However, the location of these residues relative to the front of 
the peptide remained critical, because the addition of a single amino acid upstream of the 




Defining the N-terminal glycine degrons recognized by ZYG11B and ZER1 
 To gain further insight into the specific degron motifs recognized by ZYG11B and 
ZER1, we examined a larger number of potential peptide-GFP substrates commencing with 
glycine (fig. S12). These could be divided into three categories: peptides containing degrons 
fully stabilized upon ZYG11B mutant alone (fig. S12A), peptides containing degrons 
stabilized partially upon ZYG11B mutant alone, but which required combined ZYG11B and 
ZER1 mutant for complete stabilization (fig. S12B), and peptides containing degrons for 
which full redundancy was observed between ZYG11B and ZER1 (fig. S12C). For the vast 
majority of the peptides in the latter two categories an aromatic residue (H, F or Y) was 
located downstream of the terminal glycine, supporting the idea that ZER1 might 
preferentially recognize bulky residues located further along the peptide chain (fig. S12D).
 We tested this hypothesis more rigorously by repeating the saturation mutagenesis 
experiments in the genetic background of either ZYG11B ablation or ZER1 ablation (data 
S4, B and C). The results for some representative peptides are shown in Fig. 5A-D and fig. 
S13. Mutations conferring instability in wild-type cells were identical to those conferring 
instability in ZER1 mutant cells (Fig. 5, A and B). Therefore, these residues comprise the 
minimal N-terminal glycine degron, which is recognized by ZYG11B. Conversely, the ZER1 
degron (as revealed in ZYG11B mutant cells) is more extensive, because mutations two or 
more residues downstream of the terminal glycine interfered with degradation (Fig. 5, C and 
D). Overall, these data support a model whereby both ZYG11B and ZER1 target substrates 
with exposed glycine residues at their N-termini; however, the recognition motif for ZYG11B 
is relatively small, comprising just the terminal glycine and the following residue, whereas 
the recognition motif for ZER1 may extend three or more residues along the polypeptide 




N-terminal glycine degrons are depleted from metazoan proteomes 
 GPS-peptidome technology has already identified a suite of degron motifs lying at the 
C-terminus of human proteins (13). All of these degron motifs are depleted from the human 
proteome (13), suggesting evolutionary pressure to avoid degradation by E3 ligases that 
target terminal degrons. We thus examined the abundance of N-terminal glycine degrons in 
eukaryotic proteomes. As is the case for the residue at the extreme C-terminus of eukaryotic 
proteins (13), the identity of the residue following the initiator methionine at the N-terminus 
was far more variable than at all neighboring positions, suggesting that its properties are 
particularly important (Fig. 5E). Nonetheless, glycine was encoded at almost exactly the 
expected frequency at the second position across a range of metazoan model organisms (Fig. 
5F, blue dots). However, classifying glycine residues as those favored (G followed by F, G, 
H, L, M or Y) or disfavored (G followed by D, E, I, N, P, R, S or T) for CRL2-mediated 
degradation revealed that, compared to sequences located internally, N-terminal glycine 
degron motifs are depleted from animal proteomes (Fig. 5F, orange dots), while N-terminal 
glycine motifs that are not efficiently recognized by ZYG11B and ZER1 are correspondingly 
enriched (Fig. 5F, green dots). As a control we performed a similar analysis on a panel of 
reference fungal proteomes, which possess Cul2 but no ZYG11B-family ortholog (20). 
Consistent with the idea that there should be no selective pressure to avoid N-terminal 
glycine degrons in the absence of Cul2ZYG11B and Cul2ZER1, no such relationship was 
observed as in animal proteomes (Fig. 5G). Thus, the avoidance of N-terminal glycine motifs 




ZYG11B and ZER1 target protein fragments bearing N-terminal glycine following 
proteolytic cleavage 
Endoproteolysis generates an additional source of terminal degrons (21–23). Caspase 
cleavage preferentially occurs immediately upstream of glycine residues (Fig. 6A). Indeed, of 
the ~1800 known human caspase cleavage sites, approximately one-third result in the 
exposure of glycine at the N-terminus of the downstream fragment (24), suggesting a 
potential role for ZYG11B and ZER1 in the degradation of proteins cleaved during apoptosis. 
Moreover, in contrast to the situation at the native N-termini of human proteins (Fig. 5F), we 
found that N-terminal glycine degrons favoring CRL2-mediated degradation were enriched at 
caspase cleavage sites (Fig. 6B).  
We used GPS to assess a potential role for ZYG11B and ZER1 in the removal of 
proteolytic fragments. We generated a Ub-GPS peptide library in which the 24 residues 
downstream of all caspase cleavage events annotated in Degrabase (24) and PROSPER (25) 
were fused to the N-terminus of GFP, and profiled the stability of these peptide-GFP fusions 
in wild-type cells versus combined ZYG11B/ZER1 mutant cells (Fig. 6C and data S6). The 
results confirmed that Cul2ZYG11B and Cul2ZER1 could target many caspase cleavage products: 
225 substrates were stabilized >0.5 PSI units in both ZYG11B/ZER1 double mutant lines, of 
which 219 (97%) harbored an N-terminal glycine residue (Fig. 6D; the GPS profiles of some 
example substrates are shown in Fig. 6E and fig. S14A).  
We validated these findings in two ways. First, for a panel of example cleavage 
products exposing N-terminal glycine degrons, we verified that the full-length protein 
fragments downstream of the cleavage site were stabilized in ZYG11B/ZER1 double mutant 
cells (Fig. 6F). Second, we demonstrated that these fragments would also be substrates for 
ZYG11B and ZER1 following endoproteolytic cleavage. Our initial attempts to perform these 
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experiments by inducing the dimerization of caspase 9 (26) resulted in rapid cell death. 
Therefore, in order to decouple proteolytic cleavage from cell death, we engineered mutant 
versions of four example substrates in which the caspase cleavage site was replaced with the 
Tobacco Etch Virus (TEV) protease cleavage site (Fig. 6G). TEV protease recognizes the 
amino acid sequence ENLYFQ/G (where / represents the cleavage position), thus exposing 
an N-terminal glycine on the downstream fragment, and is active when expressed in 
mammalian cells (27, 28). Upon expression of TEV protease, we observed destabilization of 
the downstream cleavage products bearing N-terminal glycine degrons in wild-type cells, but 
this effect was abrogated in ZYG11B/ZER1 double mutant cells (Fig. 6G and fig. S14B). 
Thus, ZYG11B and ZER1 are likely to be involved in the clearance of proteolytic fragments 
following caspase cleavage during apoptosis.   
 
ZYG11B and ZER1 function in the quality control of N-myristoylated proteins
 Finally we considered whether the recognition of N-terminal glycine degrons might 
be conditionally regulated through post-translational modifications. Intriguingly, N-
myristoylation, the process through which the 14-carbon fatty acid myristate is attached to the 
N-terminus of a subset of eukaryotic proteins (29), occurs exclusively on N-terminal glycine 
(Fig. 7A). Given that our mutagenesis experiments showed that addition of just a single 
amino acid to the N-terminus prevented ZYG11B- and ZER1-mediated recognition, we 
reasoned that N-myristoylation would prevent CRL2-mediated degradation via N-terminal 
glycine. Thus we hypothesized that ZYG11B and ZER1 might play an important role in 
“myristoylation quality control”, degrading proteins bearing N-terminal glycine degrons 
conditionally exposed following a failure of N-myristoylation.      
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 Given that the N-myristoyltransferase enzymes (NMT1 and NMT2 in human cells) 
require less than the first 20 residues for substrate recognition (29), we reasoned that the 
peptide-GFP fusion proteins expressed from our N-terminome Ub-GPS library should 
undergo native N-myristoylation. In order to examine the effect of N-myristoylation on 
protein stability, we profiled the N-terminome Ub-GPS library in the presence or absence of 
NMT1/2 (Fig. 7B and data S3C). Although we were not able to generate clones in which 
both NMT1 and NMT2 were completely ablated following CRISPR/Cas9-mediated gene 
disruption – a finding consistent with the notion that N-myristoylation is an essential process 
(30) – we did isolate three clones that retained only residual levels of one NMT enzyme as 
assessed by immunoblot (Fig. 7C). When we analyzed the composition of all the peptide-
GFP fusion proteins whose stability was significantly reduced in all three NMT1/2 mutant 
clones, N-terminal glycine was the most enriched feature (Fig. 7D). Thus, a failure to 
undergo N-myristoylation can lead to instability of the unmodified protein.   
 To investigate a possible role for ZYG11B and ZER1 in this process, we examined 
the stability of a panel of example substrates (fig. S15A) wherein N-terminal peptides derived 
from proteins known to undergo N-myristoylation (31) were expressed in the presence and 
absence of both NMT1/2 and ZYG11B/ZER1. These peptide-GFP fusion proteins were 
indeed efficiently myristoylated, as evidenced by membrane localization in wild-type cells 
but not in NMT1/2 mutant cells (fig. S15B). Validating the screen results, in each case we 
observed destabilization of the peptide-GFP fusion protein upon loss of NMT1/2 (Fig. 7E, 
gold histograms); moreover, ZYG11B and ZER1 were primarily responsible for this 
instability, because complete or near-complete re-stabilization was observed upon ablation of 
both NMT1/2 and ZYG11B/ZER1 (Fig. 7E, purple histograms). The true magnitude of this 
effect is likely to be even greater, because addition of the small molecule NMT1/2 inhibitor 
IMP-1088 (32) to the NMT1/2 mutant clones, thereby inhibiting the residual N-
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myristoyltransferase activity remaining in the cell, further enhanced the destabilization of the 
peptide-GFP substrates (fig. S15C). Moreover, the small degree of stabilization observed 
with some of the fusion proteins upon ablation ZYG11B and ZER1 in wild-type (that is, 
NMT1/2-sufficient) cells (Fig. 7E, top row) suggested that some fraction of protein 
molecules do normally escape N-myristoylation, emphasizing the necessity for a degradative 
mechanism to remove these aberrant species. 
Lastly, we wanted to validate that endogenous N-myristoylated proteins behaved in a 
similar manner. Indeed, we observed a significant reduction in the steady-state levels of a 
panel of example substrates in NMT1/2 mutant cells, which was abrogated upon concurrent 
ablation of ZYG11B and ZER1 (Fig. 7F). However, unlike the complete or near-complete 
stabilization that we observed using the peptide-GFP fusion constructs (Fig. 7E), here dual 
ZYG11B/ZER1 mutant only resulted in partial re-stabilization. Thus, in the context of full-
length proteins, multiple degrons in addition to N-terminal glycine may be exposed following 
a failure of N-myristoylation, rendering them substrates for additional E3 ligases. Altogether, 
these data demonstrate a physiological role for ZYG11B and ZER1 in the surveillance of 
myristoylated proteins: successful N-myristoylation shields proteins from degradation, but a 
failure to undergo N-myristoylation results in the exposure of N-terminal glycine degrons and 
CRL2-mediated degradation (Fig. 7G). 
 
Discussion 
 Here we exploited GPS technology to examine directly the contribution of N-terminal 
sequences to protein stability across the human proteome. Unexpectedly, in addition to 
targeting abnormal proteins lacking an initiator methionine, we discovered that UBR-family 
E3 ligases also targeted proteins with a native N-terminus in which an arginine or lysine 
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residue follows an intact initiator methionine. We also found that cysteine exposed at the N-
terminus of GFP conferred instability in a UBR-dependent manner. Nitric oxide-mediated 
oxidation of N-terminal cysteine renders it a substrate for arginylation by ATE1 and hence 
UBR-mediated degradation (16). However, here substrates bearing N-terminal cysteine were 
not stabilized to the same extent in ATE1 mutant cells as in cells lacking UBR proteins; thus, 
if UBR proteins do not directly bind N-terminal cysteine, an ATE1-independent pathway 
must exist that permits this class of degrons to be recognized by UBR E3 ligases. 
Most significantly we uncovered an additional N-degron pathway centered on N-
terminal glycine. There are intriguing mechanistic similarities between the ZYG11B- and 
ZER1-mediated recognition of N-terminal glycine degrons and the KLHDC2-, KLHDC3 and 
KLHDC10-mediated recognition of C-terminal glycine degrons (13), with both processes 
involving multiple related members of CRL2 substrate adaptor families. Like the Kelch 
repeats found in the KLHDC family proteins, the leucine-rich repeats and the armadillo-like 
repeats present in the ZYG11 family adaptors also have the propensity to form solenoid 
structures (33), raising the possibility of a common structural mode through which terminal 
glycine residues are engaged (34). Furthermore, like their C-terminal counterparts, the 
ZYG11 family of substrate adaptors have also shaped the proteome, with N-terminal glycine 
degrons being broadly avoided across metazoa.  
Our data suggests two contexts in which the targeting of N-terminal glycine degrons 
may play an important physiological role. N-myristoylation is a post-translational 
modification regulating the membrane localization and other properties of several hundred 
human proteins (29), a group which comprises notable members including Arf family 
GTPases, G protein alpha subunits and Src family tyrosine kinases (35). We propose a model 
whereby a failure of N-myristoylation conditionally exposes N-terminal glycine degrons to 
ZYG11B and ZER1, which are normally occluded upon successful modification. Further 
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work will be required to ascertain whether other classes of terminal degrons function in 
analogous quality control pathways to ensure the efficient deposition of post-translational 
modifications.  
Furthermore, the strong enrichment for favored ZYG11B/ZER1 glycine degrons at 
the N-termini of known caspase cleavage products suggested a potential role for these CRL2 
complexes during apoptosis, and we confirmed experimentally that many caspase cleavage 
events would generate substrates efficiently degraded by Cul2ZYG11B and Cul2ZER1. After 
glycine, the next most commonly generated N-terminal residue following caspase cleavage is 
serine, accounting for ~28% of annotated caspase sites (Fig. 6A). Intriguingly, in complete 
contrast to glycine, serine is the most stabilizing residue when exposed at the N-terminus 
(Fig. 2A). Indeed, our caspase cleavage product GPS screen showed that fragments bearing 
N-terminal serine were generally extremely stable (fig. S14C). This may be useful where 
caspases need to activate a target, such as in the case of ATM, whose C-terminal cleavage 
product acts in a dominant-negative manner to prevent DNA repair during apoptosis (36), or 
RAD21, whose C-terminal cleavage product acts as a pro-apoptotic factor (37). 
The significance of this glycine-specific N-degron pathway to human biology is 
underscored by the fact that the frequency of heterozygous loss-of-function mutations in 
humans for both ZYG11B and ZER1 is far lower than would be predicted. ZYG11B and 
ZER1 both have a pLi value of 1 in the ExAC database (38), indicating that loss-of-function 
variants are strongly selected against in the heterozygous state thereby demonstrating potent 
haploinsufficiency and counter selection in humans. Misregulation of Src-family tyrosine 
kinases could be deleterious to development. In C. elegans, the ZYG11 ortholog is required 
for the metaphase to anaphase transition and M phase exit at meiosis II (20, 39, 40). In 
humans ZYG11B and ZER1 are both expressed in the testes and ovaries, and hence a similar 
role in the regulation of meiosis could also explain the strong selection against loss-of-
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function mutations. Altogether, the comprehensive analysis of N-terminal degrons presented 
here has illuminated multiple new aspects of N-degron proteolytic pathways and revealed that 




















Materials and Methods: 
Cell Culture 
HEK-293T (ATCC® CRL-3216™) cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum 
(HyClone) and penicillin/streptomycin (Thermo Fisher Scientific). 
 
Transfection and lentivirus production 
Lentivirus was generated through the transfection of HEK-293T cells using PolyJet In 
Vitro DNA Transfection Reagent (SignaGen Laboratories). Cells seeded at approximately 
80% confluency were transfected as recommended by the manufacturer with the lentiviral 
transfer vector plus four plasmids encoding Gag-Pol, Rev, Tat and VSV-G. The media was 
changed 24 h post-transfection and lentiviral supernatants collected a further 24 h later. Cell 
debris was removed by centrifugation (800 x g, 5 min) and virus was stored in single-use 
aliquots at -80°C. Transduction of target cells was achieved by adding the virus in the 
presence of 8 μg/ml hexadimethrine bromide (Polybrene, Sigma-Aldrich). 
 
Inhibitors 
The proteasome inhibitor Bortezomib was obtained from APExBio and the pan-CRL 
inhibitor MLN4924 was obtained from Active Biochem; both were used at a final 
concentration of 1 µM. The NMT1/2 inhibitor IMP-1088 was purchased from Cayman 
Chemical and was used at a final concentration of 1 µM for 24 h. 
  
Antibodies 
Primary antibodies used in this study were: rabbit anti-UBR1 (Bethyl, A302-988A), 
rabbit anti-UBR2 (Bethyl, A305-416A), rabbit anti-UBR4 (Bethyl, A302-278A), rabbit anti-
GFP (Abcam, ab290), rabbit anti-FOXJ3 (Bethyl, A303-107A), rabbit anti-ALKBH1 
(Abcam, ab195376), rabbit anti-CHMP3 (Bethyl, A305-397A), mouse anti-vinculin (Sigma, 
V9131), rabbit anti-Fyn (Cell Signaling, 4023T), rabbit anti-LAMTOR (Cell Signaling, 
8975T), rabbit anti-Yes (Cell Signaling, 3201S), rabbit anti-Lyn (Bethyl, A302-683A-T), 
rabbit anti-NDUFAF4 (ABclonal, A14345), rabbit anti-Src (Cell Signaling, 2123T) and 
rabbit anti-GAPDH (Cell Signaling, 5174). The HA and FLAG epitope tags were detected 
using rat anti-HA peroxidase (Sigma-Aldrich, 12013819001) and rabbit anti-FLAG 
peroxidase (Cell Signaling, #2044S). HRP-conjugated goat anti-rabbit IgG secondary 
antibody was obtained from Jackson ImmunoResearch (#111-035-003). 
 
Plasmids 
Lentiviral vectors encoding dominant-negative Cullin constructs were a generous gift 
from W. Harper. For exogenous expression of CRL2 substrate adaptors, the pHRSIN-PSFFV-
GFP-WPRE-PPGK-Hygro vector was used (a gift from P. Lehner), with the constructs cloned 
in in place of GFP using the Gibson assembly method (NEBuilder HiFi Cloning Kit). 
Plasmids encoding ZYG11A and ZYG11B were obtained from Addgene (plasmids #110550 
and #110551, deposited by E. Kipreos (41)), while an entry vector encoding ZER1 was 
obtained from the Ultimate ORF Clone collection (Thermo Fisher Scientific). A plasmid 
encoding TEV protease was also obtained from Addgene (plasmid #64276, deposited by X. 
Shu (27)). 
For individual CRISPR/Cas9-mediated gene disruption experiments, the lentiCRISPR 
v2 vector was used (Addgene #52961, deposited by Feng Zhang). Oligonucleotides encoding 
the top and bottom strands of the sgRNAs were synthesized (IDT), annealed and 
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phosphorylated (T4 PNK; NEB) and cloned into the lentiCRISPR v2 vector as described 




















Analysis of HEK-293T cells by flow cytometry was performed on a BD LSRII 
instrument (Becton Dickinson) and the resulting data was analyzed using FlowJo. Cell 
sorting was performed on a MoFlo Astrios (Beckman Coulter). 
 
Generation of Ub-GPS libraries 
Human protein coding sequences were downloaded from the Gencode database (release 
27). The first 72 nucleotides of entries that (1) started with a methionine residue, (2) had a 
transcript_support_level equal to 1 or 2 and (3) were common to both the Ensembl and 
Havana databases were included in the oligonucleotide design. After removal of identical 72-
mer sequences, the final N-terminome library consisted of a total of 24,638 sequences. The 
oligonucleotide pool was synthesized by Agilent Technologies and amplified by PCR (Q5 
Hot Start High-Fidelity DNA Polymerase, NEB). The PCR product was then cloned into the 
Ub-GPS vector between a unique SalI site engineered into the 3’ end of the ubiquitin gene 
and a unique NdeI site at the 5’end of GFP using the Gibson assembly method (NEBuilder 
HiFi Cloning Kit), such that the resulting vector encoded the peptides immediately 
downstream of ubiquitin, followed by a short linker (ATSALGT) and GFP (commencing 
SKGEEL-). At least 100-fold representation of the library was maintained at each step. 
Ub-GPS libraries for saturation mutagenesis were generated in an identical manner. For 
each peptide selected for analysis, each amino acid encoded at position 2 through to position 
10 was mutated to all other possible 19 amino acids. For each peptide 9 reference sequences 
were also synthesized, in which the same wild-type amino acid sequence was encoded by 
different nucleotide sequences. 
Two databases were used to collate cleavage products for the caspase cleavage site Ub-
GPS library: Degrabase (24) and PROSPER (25). All annotated cleavage sites in human 
proteins occurring after aspartic acid in each databases were included for oligonucleotide 
design, which, after removal of duplicates, resulted in a total of 2,234 sequences. Amino acid 
sequence were converted into nucleotide sequences using the following codons: 
A: GCC, C: TGC, D: GAC, E: GAG, F: TTC, G: GGC, H: CAC, I: ATC, K: AAG, L: CTG, 
M: ATG, N: AAC, P: CCC, Q: CAG, R: AGA, S: TCC, T: ACC, V: GTG, W: TGG and Y: 
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TAC. The oligonucleotide pool was synthesized by Agilent Technologies and amplified and 




GPS plasmid libraries were packaged into lentiviral particles which were used to 
transduce HEK-293T cells at a multiplicity of infection of ~0.2 (achieving approximately 
20% DsRed+ cells) and at sufficient scale to achieve ~500-fold coverage of the library (a total 
of ~12 million transduced cells in the case of the human N-terminome library). Puromycin 
(1.5 µg/ml) was added two days post-transduction to eliminate untransduced cells. Surviving 
cells were pooled, expanded and then partitioned by FACS into six bins 7 days post-
transduction based on the GFP/DsRed ratio. Genomic DNA was extracted from each of the 
pools separately (Gentra Puregene Cell Kit, Qiagen) and the fusion peptides amplified by 
PCR (Q5 Hot Start Polymerase, NEB) using a forward primer annealing to the end of the 
ubiquitin gene and a reverse primer annealing to the front of GFP; sufficient reactions were 
performed to amplify a total mass of DNA equivalent to the mass of genomic DNA from 
cells representing 500-fold coverage of the library. All PCR products were pooled, and one-
tenth of the mix was purified using a spin column (Qiagen PCR purification kit). Finally, 200 
ng of the purified PCR product was used as the template for a second PCR reaction using 
primers to add the Illumina P5 sequence and a 7 bp ‘stagger’ region to the 5’ end, and 
Illumina indexes and P7 sequence at the 3’ end. Samples to be multiplexed were then pooled, 
purified on an agarose gel (QIAEXII Gel Extraction Kit, Qiagen) and sequenced on an 
Illumina NextSeq instrument. 
 
CRISPR screens 
A custom sgRNA library was designed targeting 43 E2 enzymes, 11 core CRL 
components and 109 CRL2/5 adaptors at a depth of 6 sgRNAs per gene. The sgRNA 
sequences together with flanking BbsI restriction enzymes recognition sites were synthesized 
by Twist Bioscience. The oligonucleotide pool was amplified by PCR (Q5 Hot Start 
Polymerase, NEB) and the product purified (Qiagen PCR purification kit) and digested with 
BbsI (NEB). The digested product was concentrated by ethanol precipitation and then 
visualized on a 10% TBE PAGE gel (Thermo Fisher Scientific) stained with SYBR Gold 
(Thermo Fisher Scientific). DNA was isolated from the 28 bp band using the ‘crush-and-
soak’ method, concentrated by ethanol precipitation, and then cloned into lentiCRISPR v2 
(Addgene #52961) digested with BsmBI (NEB). 
The sgRNA library DNA was packaged into lentiviral particles. HEK-293T cells stably 
expressing unstable peptide-GFP fusion proteins were transduced at a multiplicity of 
infection of ~0.3 at sufficient scale to maintain at least 1000-fold representation of the library. 
Untransduced cells were eliminated through puromycin selection commencing two days post-
transduction. The top ~5% of the surviving cells based on the GFP/DsRed ratio were isolated 
by FACS, which was performed 7 days post-transduction. For each screen genomic DNA 
was extracted from both the sorted cells and the unselected library as a reference. The 
sgRNAs in both pools were amplified by PCR and sequenced on an Illumina NextSeq 
instrument. 
 
Immunoprecipitation and immunoblotting 
HEK-293T cells stably expressing epitope-tagged CRL2 substrate adaptors and peptide-
GFP fusions were grown in 10 cm plates. Following treatment with Bortezomib (1 µM, 5 h), 
cells were lysed in ice-cold lysis buffer (50 mM Tris, 100 mM NaCl, 0.5% NP-40, pH 7.5 
supplemented with EDTA-free protease inhibitor tablet and Phos-Stop phosphatase inhibitor 
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tablet (Roche)) for 30 min on ice. Nuclei were pelleted by centrifugation (14,000 x g, 10 min, 
4°C). Beads coated with anti-HA (Pierce anti-HA magnetic beads, Thermo Fisher Scientific) 
or anti-FLAG (anti-FLAG M2 magnetic beads, Sigma-Aldrich) antibodies were added to the 
supernatants and incubated with rotation overnight at 4°C. The beads were then washed three 
times with lysis buffer before bound proteins were eluted upon incubation with SDS-PAGE 
sample buffer (95°C, 10 min). Proteins were subsequently resolved by SDS-PAGE (NuPAGE 
Bis-Tris gels, Thermo Fisher Scientific) and transferred to a nitrocellulose membrane (Trans-
Blot Turbo System, Bio-Rad) which was then blocked in 10% nonfat dry milk in PBS + 0.1% 
Tween-20 (PBS-T). The membrane was incubated with primary antibody overnight at 4°C, 
and then, following three washes with PBS-T, HRP-conjugated secondary antibody was 
added for 1 h at room temperature. Following a further three washes in PBS-T, reactive bands 




UBR KO clone #2 cells stably expressing peptide-GFP fusions growing in 15 cm plates 
were lysed as described above, and immunoprecipitation performed in a similar way using 
GFP-Trap_MA magnetic agarose beads (Chromotek). Elution of the peptide- GFP fusion 
proteins was achieved by treatment with 2 M glycine for 1 min, followed by neutralization 
with 1 M Tris base, pH 10.4. Eluted proteins were reduced using DTT (Thermo Fisher) and 
alkylated with iodoacetamide (Sigma). Following TCA precipitation (Sigma), proteins were 
digested with Glu-C (Thermo Fisher) then cleaned up on C-18 stage tips (3M).  
Mass spectrometry data were collected using a Q Exactive mass spectrometer (Thermo 
Fisher) coupled with a Famos Autosampler (LC Packings) and an Accela600 liquid 
chromatography pump (Thermo Fisher). Peptides were separated on a 100 μm inner diameter 
microcapillary column packed with ∼25 cm of Accucore C18 resin (2.6 μm, 150 Å, Thermo 
Fisher). Peptides were separated using a 120 gradient of 5 to 25% acetonitrile in 0.125% 
formic acid at a flow rate of ∼300 nl/min. The scan sequence began with an Orbitrap MS1 
spectrum with resolution 70,000, scan range 300−1500 Th, automatic gain control (AGC) 
target 1 × 105, maximum injection time 250 ms, and centroided data type. The top twenty 
precursors were selected for MS2 analysis which consisted of HCD (high-energy collision 
dissociation) with the following parameters: resolution 17,500, AGC 1 × 105, maximum 
injection time 100 ms, isolation window 1.6 Th, normalized collision energy (NCE) 27, and 
centroid spectrum data type. Unassigned charge states were excluded from MS2 analysis, but 
singly charged species were included. Dynamic exclusion was set to automatic. Mass spectra 
were processed using a Sequest-based in-house software pipeline.  
 
Bioinformatics 
N-terminome Ub-GPS screen. Raw Illumina reads derived from each GPS bin were first 
trimmed of constant sequences derived from the Ub-GPS vector backbone using Cutadapt 
(43). Resulting 72 nt reads were mapped to the reference input library using Bowtie 2 (44), 
and count tables were generated from reads that aligned perfectly to the reference sequence. 
Following correction for sequencing depth, the protein stability index (PSI) metric was 
calculated for each peptide-GFP fusion. The PSI score is given by the sum of multiplying the 
proportion of reads in each bin by the bin number (1-6 in this case), thus yielding a stability 
score between 1 (maximally unstable) and 6 (maximally unstable):   
PSI = ∑ 𝑅𝑖 ∗ 𝑖6𝑖=1     
(where i represents the number of the bin and Ri represents the proportion of Illumina 
reads present for a peptide in that given bin i). Read counts and associated stability score for 




Prediction of destabilizing N-terminal motifs. The stability data derived from the Ub-
GPS N-terminome screen was used to identify potential destabilizing N-terminal degron 
motifs (Fig. 2, C and D). Varying exactly two residues at a time between position 2 and 
position 7, for all possible combinations of di-peptide motifs (allowing gaps) the mean PSI of 
all peptides containing that motif at the front of the peptide (that is, immediately following 
the initiator methionine) was compared to the mean PSI of all peptides containing the same 
motif at any internal location within the 24-mer peptide. The full data for all possible N-
terminal motifs is tabulated in data S2. 
 
N-terminome Ub-GPS screen in different genetic backgrounds. The Ub-GPS N-
terminome screens with the UBR mutant clones and the ZYG11B and ZER1 mutant cells 
were performed in a similar manner as above, except that only the half of the N-terminome 
library comprising peptides bearing an initiator methionine was used. Read counts for all 
peptide-GFP fusions are detailed in data S3A. Subsequently, comparisons between wild-type 
cells and combined ZYG11B/ZER1 mutant cells (data S3B) and between wild-type, control 
(AAVS1) mutant and three NMT1/2 mutant clones (data S3C) were performed in a similar 
way. In each case, a ΔPSI score was generated for each peptide-GFP fusion reflecting the 
difference in raw PSI scores between the wild-type or control mutant cells and the 
experimental mutant cells. For the plots shown in Fig. 3 and fig. S3, peptide-GFP fusions 
were defined as UBR substrates if they were stabilized >0.8 PSI units (Fig. 3E) or >0.6 PSI 
units (fig. S3A-D) in the UBR KO clone compared to control cells, but also not stabilized 
>0.3 PSI units in either ZYG11B or ZER1 mutant cells. The logoplots shown in fig. S3E-H 
were generated with iceLogo (45) and rendered using Seq2Logo (46): the ‘experimental set’ 
comprised all peptides starting with the indicated motif that were identified as a UBR 
substrate in any of the three UBR KO clones, the ‘reference set’ comprised all peptides in the 
N-terminome library starting with that same motif, and the ‘percentage difference’ scoring 
system was used. Residues significantly enriched at P < 0.05 are displayed. For the heatmap 
shown in Fig. 7D, peptide-GFP fusions destabilized >0.5 PSI units in all three NMT1/2 
mutant clones were included for analysis. 
 
Saturation mutagenesis Ub-GPS screens. The heatmaps displayed in Fig. 3G-I, fig. 
S4A-C, Fig. 4B and fig. S5 illustrate the difference between the PSI for each individual 
mutant peptide and the median PSI of all the unmutated peptides; the darker the red color, the 
greater the stabilizing effect of the mutation. For the heatmaps shown in Fig. 5A-C and fig. 
S12 the color scales indicate the raw PSI stability measurement, which lies between 1 
(maximally unstable; dark blue) and 6 (maximally stable; dark red); the exception is the 
comparison between ZYG11B mutant and ZER1 mutant cells (right columns) where a  ΔPSI 
score reflecting the difference between raw PSI score in ZYG11B mutant cells and ZER1 
mutant cells for each peptide is depicted. The full data for all mutant peptides in all genetic 
backgrounds is detailed in data S4A-C.  
 
CRISPR screens. Constant regions derived from the backbone of the lentiCRISPR v2 
expression vector were removed from Illumina reads using Cutadapt, and count tables were 
generated from the remaining variable portion of the sgRNA sequences using Bowtie 2. The 
Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) algorithm (47) 
was used to rank the performance of individual genes targeted by multiple sgRNAs enriched 
in the selected cells versus the unsorted populations. The full MAGeCK output for each 
screen is detailed in data S5. For the scatterplots shown in Fig. 4E and fig. S8B, the 
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MAGeCK score plotted on the y-axis is calculated as the negative log10 of the ‘pos|score’ 
value generated by MAGeCK.   
 
Proteome composition analysis. Canonical protein sequences were downloaded from the 
Swiss-Prot database. For each position between position 2 and position 10 at the N-terminus 
of the proteins the total abundance of each amino acid was quantified, expressed as a 
proportion of the total number of protein sequences, and then normalized to the mean 
proportion observed across the 9 N-terminal residues between position 2 and position 10. For 
the analysis of N-terminal glycine degrons shown in Fig. 5, F and G, we further categorized 
glycine residues as either ‘favored’ for CRL2-mediated degradation through ZYG11B and 
ZER1 if they were followed by F, G, H, L, M or Y, or ‘disfavored’ if followed by D, E, I, N, 
P, R, S or T. The mean abundance of Gfavored and Gdisfavored across the 8 N-terminal residues 
between position 3 and position 10 was then compared to their abundance at position 2. For 
the analysis of human caspase cleavage sites presented in Fig. 6A, all unique cleavage sites 
occurring downstream of aspartic acid (D) annotated in Degrabase 1.0 (24) were analyzed 
using iceLogo. In Fig. 6B, all unique cleavage sites occurring downstream of aspartic acid 
(D) and upstream of glycine (G) were analyzed; the frequency of Gfavored and Gdisfavored at the 
N-terminus of these caspase cleavage products was compared to the frequency of Gfavored and 
Gdisfavored at all glycine residues in the human proteome. 
 
Caspase cleavage site Ub-GPS screen. The Ub-GPS screen with peptides derived from 
human caspase cleavage sites was analyzed in the same way as above, generating a ΔPSI 
score for each peptide reflecting the difference in raw PSI scores between either control 
(AAVS1) mutant cells or combined ZYG11B/ZER1 double mutant cells versus wild-type 
cells (data S6). For the heatmap shown in Fig. 6D, peptide-GFP fusions stabilized >0.5 PSI 
units in both ZYG11B/ZER1 double mutant cell lines but <0.25 PSI units in control knockout 
cells were included; the intensity of the colors represent the depletion (blue) or enrichment 
(red) of each amino acid comparing this pool of ZYG11B/ZER1 substrates to all peptides 
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Figure Legends:  
 
Figure 1. GPS profiling of the human N-terminome. 
(A) Schematic representation of the N-terminome GPS screen, in which the first 24 residues 
of all human proteins were expressed in the Ub-GPS vector as N-terminal fusions to GFP.  
(B) Distribution of protein stability scores observed from the screen depicted in (A). 
(C) Boxplots showing the distribution of stability scores for all peptides commencing with 
the indicated amino acid, when encoded either with (blue boxes) or without (orange) an 
upstream methionine residue. 
(D-F) Heatmaps depicting the mean stability score for all peptides commencing with the 
indicated two amino acids, when encoded either with (E) or without (D) an upstream 













Figure 2. Identification of degron motifs located at protein N-termini. 
(A and B) The effect of peptide composition on protein stability. Heatmaps showing the 
relative depletion (blue) or enrichment (red) of each amino acid across all positions of the 23-
mer peptide amongst unstable peptides (A) versus stable peptides (B).  
(C-F) Computational prediction of N-terminal degrons. (C) For all possible combinations of 
di-peptide motifs, the mean difference in stability between peptides containing the motif at 
the extreme N-terminus (that is, immediately following the initiator methionine) was 
compared to all peptides containing the motif at any other internal position in the peptide. (D) 
Classes of N-terminal degrons. The majority of the top 100 predicted destabilizing N-
terminal motifs encoded either glycine (G2), lysine (K2), arginine (R2) or cysteine (C2) at the 
second position; some example motifs are annotated. (E) Boxplots showing the distribution 
of stability scores for all peptides in which the indicated residues were encoded at the second 
position (colored boxes) versus any other internal position within the peptide (gray boxes). 
(F) Boxplots showing the distribution of stability scores for all peptides with the indicated 










Figure 3. Assessing the repertoire of UBR substrates among the human N-terminome. 
(A-C) Assessing UBR-mediated degradation via N-terminal degron motifs. (A) 
CRISPR/Cas9-mediated generation of clones expressing reduced levels of UBR1, UBR2 and 
UBR4. (B) Functional validation of UBR KO clones. Optimal Arg/N-end rule substrates were 
highly unstable in wild-type cells, but not in UBR KO clone #2 as measured by flow 
cytometry. See also fig. S2A. (C) UBR proteins target example peptide-GFP reporters in 
which lysine, arginine or cysteine, but not glycine, are encoded at the second position. N-
terminal peptides derived from the indicated genes were expressed in wild-type or UBR KO 
clone #2 using the Ub-GPS system and their stability assessed by flow cytometry.  
(D-F) Global identification of N-terminal UBR substrates. (D) Schematic representation of 
the GPS screen. (E) Venn diagram summarizing the substrates stabilized >0.8 PSI units 
across the three UBR KO clones. (F) Heatmap showing the relative enrichment (red) or 
depletion (blue) of each amino acid across all positions of the 23-mer peptide comparing 
peptides stabilized in two or more of the UBR KO clones relative to the whole N-terminome 
library. See also fig. S4. 
(G-I) Characterization of N-terminal UBR degrons through saturation mutagenesis. Each of 
the first ten residues of the N-terminal peptides derived from ZNF334 (commencing MK-) 
(G), AHRR (commencing MR-) (H) and CDX1 (commencing (MC-) (I) were mutated to all 
other possible residues and their stabilities measured by FACS and Illumina sequencing. The 
darker the color, the greater the degree of stabilization compared to the wild-type sequence. 






Figure 4. Cul2ZYG11B and Cul2ZER1 target N-terminal glycine. 
(A) Glycine at the N-terminus can act as a potent degron. The N-terminal peptide derived 
from SNX11 and a mutant version lacking the initiator methionine (ΔMet) were highly 
unstable, whilst mutant versions in which the terminal glycine was mutated to serine (G2S) or 
in which a serine residue was added between the initiator methionine and the glycine residue 
(add S) were not. See also fig. S6A. 
(B) Defining N-terminal glycine degrons through saturation mutagenesis. Each of the first ten 
residues of the SNX11 peptide were mutated to all other possible residues and their stabilities 
measured by FACS and Illumina sequencing. The darker the color, the greater the degree of 
stabilization compared to the wild-type sequence. See also fig. S6B. 
(C and D) Cul2 complexes target N-terminal glycine. Stabilization of the SNX11-GFP 
reporter upon treatment with the CRL inhibitor MLN4924 (C), and following expression of 
dominant-negative versions of Cullins (D). See also fig. S7. 
(E and F) CRISPR screens identify the Cul2 substrate adaptors responsible for the 
recognition of N-terminal glycine. (E) Results of the SNX11-GFP reporter screen, which 
highlighted two CRL2 complexes (F). See also fig. S8. 
(G-K) Cul2ZYG11B and Cul2ZER1 cooperate to target N-terminal glycine. (G) CRISPR-
mediated ablation of both ZYG11B and ZER1 was required for full stabilization of the 
SNX11-GFP reporter. (H) Exogenous expression of either ZYG11B or ZER1 rescued 
degradation of the SNX11-GFP reporter in cells lacking endogenous ZYG11B and ZER1. (I 
and J) Knockout of ZYG11B and ZER1 stabilized full-length SNX11 fused to the N-
terminus of GFP, both when expressed in the context of the Ub-GPS system (I) or without 




Figure 5. N-terminal glycine degrons are depleted from metazoan proteomes. 
(A-D) Defining the degrons recognized by ZYG11B and ZER1 through saturation 
mutagenesis. Each of the first ten residues of the SNX11 N-terminal peptide were mutated to 
all possible amino acids; the stability of each mutant in the resulting Ub-GPS library was 
measured in wild-type (A), ZER1 mutant (B) or ZYG11B mutant (C) cells. The color scale 
reflects the raw PSI measurement for each peptide-GFP fusion, such that the greater the 
intensity of the red color, the greater the stabilizing effect of the mutation. The heatmap in 
(D) illustrates the difference between the PSI in ZYG11B mutant cells versus ZER1 mutant 
cells; thus, a dark red color indicates mutations which prevent recognition by ZER1 but not 
by ZYG11B, while a dark blue color indicates mutations which permit recognition by ZER1 
but not by ZYG11B. See also fig. S13. 
(E) Normalized amino acid frequencies across the first ten residues (following the initiator 
methionine) of human proteins. 
(F and G) Depletion of N-terminal glycine degrons in metazoan proteomes. The normalized 
amino acid frequency of glycine encoded at the second position in the indicated proteomes is 
shown by the blue dots, and is further categorized depending on whether the glycine residue 
is followed by a residue favoring (orange dots) or disfavoring (green dots) CRL2-mediated 
degradation. The relationship observed across animal proteomes (F) is not apparent across 







Figure 6. ZYG11B and ZER1 target N-terminal glycine degrons generated through 
endoproteolytic cleavage. 
(A and B) Caspase cleavage preferentially generates fragments bearing N-terminal glycine. 
(A) Logoplot depicting the consensus sequence surrounding all caspase cleavage sites 
annotated in Degrabase (24). (B) Compared to their frequency across the human proteome, 
preferred glycine degrons (orange bar) are enriched at known caspase cleavage sites, while 
disfavored glycine degrons (green bar) are depleted. 
(C-E) Caspase cleavage events generate N-terminal glycine degrons targeted by ZYG11B 
and ZER1. (C) Schematic representation of the caspase cleavage product Ub-GPS screen. (D) 
Heatmap showing the relative enrichment (red) or depletion (blue) of each amino acid across 
all positions of the 23-mer peptide comparing peptides stabilized in both ZYG11B/ZER1 
double mutant cells compared to the whole caspase cleavage site library. (E) Profiles of 
example substrates. Residues flanking the caspase cleavage site (indicated by arrows) are 
shown. See also fig. S14A. 
(F and G) CRL2-mediated degradation of proteolytic cleavage products bearing N-terminal 
glycine degrons. (F) The full-length downstream caspase cleavage products of the indicated 
proteins were expressed using the Ub-GPS system, and their stability assessed in wild-type 
(gray) and dual ZYG11B/ZER1 mutant cells (red) by flow cytometry. (G) The caspase site in 
the indicated full-length ORFs was replaced with a TEV protease cleavage site. Upon TEV 
expression (blue histograms), destabilization of the downstream cleavage products bearing N-
terminal glycine degrons was observed in wild-type cells (top row), but not in dual 




Figure 7. Cul2ZYG11B and Cul2ZER1 target proteins that fail to undergo N-myristoylation 
for proteasomal degradation. 
(A) N-myristoylation occurs on N-terminal glycine.  
(B) Schematic representation of the GPS screen designed to assess the effect of loss of N-
myristoylation on protein stability.  
(C) Immunoblot validation of NMT1/2 knockout clones. Arrowheads indicate bands of the 
expected molecular weight. 
(D) Loss of N-myristoylation destabilizes peptide-GFP fusions commencing with glycine. 
The heatmap shows the relative enrichment (red) or depletion (blue) of each amino acid 
across all positions of the 23-mer peptide, comparing the 91 peptides exhibiting significant 
destabilization in all three NMT1/2 mutant clones relative to the whole N-terminome library. 
(E and F) ZYG11B and ZER1 target N-terminal glycine degrons exposed following a failure 
of N-myristoylation. (E) The first 24 amino acids from the indicated proteins were expressed 
as N-terminal fusions to GFP, and their stability in the indicated genetic backgrounds was 
measured by flow cytometry. The destabilization observed upon loss of NMT1/2 (gold 
histograms) is rescued in the absence of ZYG11B and ZER1 (purple histogram). (F) The 
abundance of the indicated myristoylated proteins was assessed by immunoblot in either 
control (AAVS1) or ZYG11B/ZER1 double mutant cells (DKO), either with or without 
simultaneous ablation of NMT1/2. Src, which did not exhibit significant destabilization in 
NMT1/2 mutant cells in the GPS screen, is shown as a negative control. 
(G) Model depicting the role of Cul2ZYG11B and Cul2ZER in the quality control of N-
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Fig. S1. Summary of known N-degron pathways.  
(A) The Arg/N-degron pathway. Proteins harboring primary type I (basic) or type II 
(bulky hydrophobic) residues at their N-terminus are targeted for proteasomal 
degradation by UBR family proteins. Secondary (D and E) destabilizing residues at the 
N-terminus can also become Arg/N-degron substrates through N-terminal arginylation, as 
can tertiary destabilizing residues (N and Q) at the N-terminus following prior 
deamidation (6). Furthermore, oxidation of N-terminal cysteine by nitric oxide, indicated 
by an asterisk, can render it a substrate for arginylation and hence UBR-mediated 
degradation (17).  
(B) The Ac/N-degron pathway. Acetylation of N-terminal residues can create degrons 
recognized by the MARCH6 E3 ubiquitin ligase (44). Cleavage of the initiator 
methionine upstream of amino acids with sufficiently small side chains results (colored 
green) in the exposure of the second residue, which can be a substrate for acetylation on 
the α-amino group mediated by NatA. The uncleaved initiator methionine upstream of the 
other amino acids (colored blue and red) can also serve as a substrates for other Nat 
enzymes (45). It is estimated that up to 80% of all human proteins are acetylated to some 
extent, with the degree of acetylation varying depending on the sequence context; N-
terminal alanine and serine are thought to be almost completely acetylated, while N-
terminal glycine and proline are rarely acetylated (45).  
(C) The Pro/N-degron pathway. Proline exposed at the N-terminus of proteins following 
methionine cleavage can act as degron recognized by GID4, the substrate recognition 






Fig. S2. Assessing the role of UBR family proteins in the degradation of proteins 
bearing N-terminal degron motifs.  
(A) Functional validation of UBR KO clone #1 and clone #3. Optimal Arg/N-degron 
substrates expressed in the Ub-GPS vector were highly unstable in wild-type HEK-293T 
cells, but were stabilized in the UBR KO clones, as measured by flow cytometry.  
(B) Assessing the role of UBR proteins in the degradation of proteins bearing candidate 
N-terminal degron motifs. Three amino acids ‘triplets’ containing putative N-terminal 
degrons were fused to the N-terminus of GFP and expressed in the context of the Ub-
GPS system in wild-type cells or UBR KO clone #2. In wild-type cells, all of the 
substrates (red histograms) exhibited some degree of instability compared to GFP alone 
(gray histograms). For three of the motifs – MR-, MK- and N-terminal cysteine – 
stabilization to the level of GFP alone was observed in UBR KO clone #2, whereas little 
or no stabilization was observed for the fusions harboring N-terminal glycine.  
(C and D) Assessing the role of N-terminal arginylation in the degradation of substrates 
bearing N-terminal cysteine. (C) Functional validation of efficient ATE1 disruption. Ub-
GPS substrates bearing tertiary (N) or secondary (D) Arg/N-degrons at their N-terminus 
were unstable in wild-type HEK-293T cells, but exhibited marked stabilization upon 
CRISPR/Cas9-mediated ablation of the arginyltransferase ATE1. (D) Loss of ATE1 does 
not fully stabilize unstable substrates bearing N-terminal cysteine. CRISPR-mediated 
disruption of ATE1 resulted in only partial stabilization of two example Ub-GPS 
substrates exposing N-terminal cysteine, which did not reach the level of stabilization 







Fig. S3. UBR substrates commencing MK- and MR- retain their initiator 
methionine.  
(A) Overview of the experiment. Peptide-GFP UBR substrates were expressed in UBR 
KO clone #2, immunoprecipitated using an anti-GFP antibody and then analyzed by mass 
spectrometry. 
(B) Mass spectra showing the N-terminal peptides identified from YWHAZ 
(commencing MK-) and RAD51C (commencing MR-). In each case, only species with 


















Fig. S4. Global identification of UBR substrates across the human N-terminome. 
(A-C) Sequence composition of UBR substrates. The heatmaps show the relative 
enrichment (red) or depletion (blue) of each amino acid across all positions of the 23-mer 
peptide comparing peptides stabilized >0.6 PSI units in UBR KO clone #1 (A), clone #2 
(B) or clone #3 (C) relative to the whole N-terminome library.  
(D) Assessing potential UBR4 substrates among the human N-terminome. As we 
observed a large number of reporters that were exclusively stabilized in UBR clone #2, 
which was the only clone that lacked UBR4 expression, we also analyzed the 
composition of these peptides separately: the heatmap shows the relative enrichment 
(red) or depletion (blue) of each amino acid across all positions of the 23-mer peptide 
comparing peptides stabilized >0.6 PSI units in UBR KO clone #2 but not in either clone 
#1 or clone #3. The similar preferences observed suggested that UBR4 might collaborate 
with UBR1 and UBR2 to enhance the degradation of their substrates, thus resulting in a 
greater number of peptide-GFP fusions showing significant stabilization.  
(E-H) Assessing the sequence context of UBR substrates. Logoplots highlighting 
residues significantly enriched at positions 3, 4 or 5, comparing all peptides identified as 
a UBR substrate in any of the UBR KO clones commencing MR- (E), MK- (F), ML- (G) 
or MI- (H) relative to the whole N-terminome library. 
(I) UBR proteins target substrates commencing ML- and MI-. The first 24 residues of the 
indicated proteins were fused to the N-terminus of GFP and expressed in wild-type cells 







Fig. S5. Characterizing N-terminal UBR degrons through synthetic mutagenesis. 
(A-C) Saturation mutagenesis of N-terminal peptides derived from GFOD2 (commencing 
MK-) (A), PTGS1 (commencing MR-) (B) and PLEKHG6 (commencing MC-) (C). A 
Ub-peptide-GPS library was generated in which each residue from the second position to 
the tenth position of the peptide was mutated to all other possible amino acids; the library 
was then expressed in HEK-293T cells and the stability of each mutant was measured by 
FACS followed by Illumina sequencing. The color scale reflects the degree of 
stabilization (measured in PSI units) for each mutant peptide-GFP fusion compared to the 
median stability of all the wild-type peptides. In addition, in order to assess the 
requirement for the degron to be positioned at the extreme N-terminus, mutants were also 
created in which each amino acid was added to the front of the peptide (that is, 
immediately after the initiator methionine). 
(D) GPS screen profiles for each of the six UBR peptide-GFP substrates selected for 
saturation mutagenesis, showing the distribution of Illumina sequencing reads across the 













Fig. S6. Synthetic mutagenesis defines the composition of N-terminal glycine 
degrons. 
(A) N-terminal glycine can serve as a degron. N-terminal peptides derived from the 
indicated genes were expressed in the context of the Ub-GPS system in HEK-293T cells. 
In each case, the wild-type peptide and a mutant version lacking the initiator methionine 
(ΔMet) were highly unstable, whereas mutant versions in which the terminal glycine was 
mutated to serine (G2S) or in which a serine residue was added between the initiator 
methionine and the glycine residue (add S) were not.  
(B-G) Saturation mutagenesis of N-terminal peptides derived from the (B) DBNDD2, (C) 
BBS9, (D) PDZRN4, (E) GIMAP5, (F) TLCD1, and (G) HBG2 genes. A Ub-peptide-GPS 
library was generated in which each residue from the second position to the tenth position 
of the peptide was mutated to all other possible amino acids; the library was then 
expressed in HEK-293T cells and the stability of each mutant was measured by FACS 
followed by Illumina sequencing. The color scale reflects the degree of stabilization 
(measured in PSI units) for each mutant peptide-GFP fusion compared to the median 
stability of all the wild-type peptides. In addition, in order to assess the requirement for 
the degron to be positioned at the extreme N-terminus, mutants were also created in 
which each amino acid was added at the front of the peptide, between the initiator 






Fig. S7. CRL2 complexes target N-terminal glycine.  
(A) Cullin-RING ligases target N-terminal glycine. N-terminal 24-mer peptides from the 
indicated genes were expressed in HEK-293T cells in the context of the Ub-GPS system. 
The stability of the peptide-GFP fusion proteins was measured by flow cytometry 
following treatment with the proteasome inhibitor Bortezomib or the pan-CRL inhibitor 
MLN4924.  
(B) N-terminal 24-mer peptides derived from the indicated genes were expressed in 
HEK-293T cells in the context of the Ub-GPS system. The cells were then transduced 
with lentiviral vectors expressing dominant-negative (DN) version of the indicated 
Cullins and stabilization of the peptide-GFP fusions was assessed by flow cytometry. 
Except for the peptide derived from the ETNPPL gene, which was also stabilized upon 
expression of dominant-negative Cul4A, expression of dominant-negative Cul2 resulted 








Fig. S8. The ZYG11 family of Cul2 adaptors target N-terminal glycine.  
(A) Schematic representation of the CRISPR screens. HEK-293T cells expressing 
unstable peptide-GFP fusions were transduced with Cas9 and a library of sgRNAs 
targeting known Cul2 and Cul5 adaptors plus sgRNAs targeting core CRL components 
and E2 enzymes. One week later the top 5% of cells based on GFP expression were 
isolated by FACS, and the sgRNAs enriched in this population were identified by 
Illumina sequencing.  
(B) CRISPR screen results, as determined using the MAGeCK algorithm to identify 
genes targeted by multiple sgRNAs enriched in the selected cells versus the unselected 
library (46).  
(C) Schematic representation of the Cul2 complexes formed using ZYG11 family 
substrate adaptors.  
(D) Expression of ZYG11 family substrate adaptors across human tissues. RNA-seq data 
from the GTEx project (20) shows that while ZYG11B and ZER1 are broadly expressed 






Fig. S9. Cul2ZYG11B and Cul2ZER1 redundantly target N-terminal glycine degrons.  
(A) Ablation of ZYG11B and ZER1 stabilizes peptide-GFP fusion proteins bearing N-
terminal glycine degrons. N-terminal 24-mer peptides derived from the indicated genes 
were stably expressed in the context of the Ub-GPS system in HEK-2923T cells. For the 
peptides derived from ZNF267 and JAK2, disruption of ZYG11B alone resulted in full 
stabilization (blue histograms), whereas for the other peptide-GFP fusions combined 
mutation of both substrate adaptors was required for full stabilization (red histograms).  
(B) ZYG11B and ZER1 associate with reporter substrates bearing N-terminal glycine 
degrons. HEK-293T cells were generated stably expressing epitope-tagged ZYG11B or 
ZER1 and peptide-GFP reporters (commencing MG-) derived from the N-terminus of 
SNX11 (left) or ZNF267 (right). Following immunoprecipitation of the substrate adaptor, 
co-immunoprecipitation of the reporter substrate was assessed by immunoblot for GFP. 
An irrelevant Cul2 adaptor (FEM1C) and an irrelevant peptide-GFP reporter derived 
from the N-terminus of RAD51C (commencing MR-) served as negative controls.  
(C and D) Cul2ZYG11B and Cul2ZER1 target full-length proteins for degradation. Full-
length open reading frames (ORFs) corresponding to the indicated genes were expressed 
as N-terminal fusions to GFP either in the context of the ubiquitin fusion system (C) or 
without upstream ubiquitin (D) and expressed in wild-type (gray histograms) or double 
mutant cells lacking ZYG11B and ZER1 expression (red histograms).  
(E) Endogenous substrates of Cul2ZYG11B and Cul2ZER1. The abundance of the indicated 
proteins in AAVS1 knockout (control) or combined ZYG11B/ZER1 double mutant cells 
was assessed by immunoblot (upper panels). The GPS screen performance of the 
corresponding N-terminal peptides (see fig. S10) is shown in the bottom panels; 
insufficient sequencing reads prevented quantification of the stability of the N-terminal 






Fig. S10. Global identification of Cul2ZYG11B and Cul2ZER1 substrates across the 
human N-terminome.  
(A) Schematic representation of the GPS experiment, in which the stability of the Ub-
GPS N-terminome library with initiator methionine was compared in wild-type HEK-
293T cells versus ZYG11B mutant, ZER1 mutant and combined ZYG11B and ZER1 
mutant cells.  
(B-D) Sequence composition of ZYG11B and ZER1 substrates. Heatmaps show the 
relative enrichment (red) or depletion (blue) of each amino acid across all positions of the 
23-mer peptide, comparing the composition of substrates stabilized in double ZYG11B 
and ZER1 mutant cells (B), ZYG11B mutant cells (C), or ZER1 mutant cells (D) relative 
to the whole N-terminome library.  
(E) GPS profiles of example substrates, showing the read distribution across the bins in 
control cells (gray) versus ZYG11B mutant cells (blue), ZER1 mutant cells (orange) or 
dual ZYG11B/ZER1 double mutant cells (red). These examples illustrate substrates 
redundantly targeted by both ZYG11B and ZER1 (N-terminal peptides derived from 
CBFA2T2 and ZNF701), substrates targeted solely by ZYG11B (N-terminal peptides 
derived from ATP4A and ZNF720), and substrates targeted solely by ZER1 (N-terminal 






Fig. S11. An N-terminal glycine residue is not absolutely critical for substrate 
recognition by Cul2ZER1.  
(A-C) Characterization of an N-terminal degron targeted by Cullin-RING E3 ligases 
commencing with proline. (A) The N-terminal peptide derived from KCNT2, 
commencing MPYLH-, was identified as a CRL substrate in the GPS screen with 
MLN4924 (fig. S6). We validated that this peptide fused to GFP was indeed stabilized by 
MLN4924 (B), and, employing dominant-negative Cullin constructs, found that it was a 
substrate for CRL2 (C).  
(D) CRISPR screen identifies ZER1 as the CRL2 adaptor responsible for the degradation 
of the KCNT2 peptide-GFP fusion. HEK-293T cells stably expressing the KCNT2 
peptide-GFP fusion in the context of the Ub-GPS system were transduced with Cas9 and 
a CRISPR sgRNA library targeting Cul2/5 substrate adaptors, and cells in which the GFP 
fusion were stabilized were isolated by FACS. Guides significantly enriched in the sorted 
cells compared to the unselected library were identified using the MAGeCK algorithm.  
(E) Individual CRISPR-mediated gene disruption experiments validating ZER1-mediated 
degradation of the KCNT2 peptide-GFP fusion.  
(F) Rescue of reporter degradation in ZER mutant cells upon exogenous expression of 
ZER1.  
(G) Saturation mutagenesis of the KCNT2 peptide identifies the critical residues for 
ZER1-mediated recognition. This revealed that the hydrophobic residues encoded at the 
third and fourth position were particularly important for ZER1 binding, with some more 
flexibility allowed at the second position. However, the positioning of the degron motif 
relative to the N-terminus of the protein remaining critical, as the addition of almost any 







Fig. S12. Exploring the degron requirements for Cul2ZYG11B versus Cul2ZER1.  
(A-D) Individual CRISPR/Cas9-mediated gene disruption experiments to identify 
additional substrates of Cul2ZYG11B and Cul2ZER1 bearing N-terminal glycine. In each 
case, N-terminal peptides derived from the indicated genes were expressed in the context 
of the Ub-GPS system in either wild-type, ZYG11B mutant, ZER1 mutant or dual 
ZYG11B/ZER1 mutant HEK-293T cells and their stability assessed by flow cytometry. 
Substrates could be grouped into three categories: (A) peptide-GFP fusions fully 
stabilized upon ablation of ZYG11B, for which no additional stabilization was observed 
in the double mutant cells, (B) peptide-GFP fusions which exhibited some degree of 
stabilization in ZYG11B single mutant cells, but for which full stabilization was only 
observed in the double mutant cells, and (C) peptide-GFP fusions which displayed no 
stabilization at all in either ZYG11B or ZER1 mutant cells but were stabilized in the 
double mutant cells. For the majority of the substrates in the latter two categories, an 
aromatic residue (histidine, phenylalanine or tyrosine) was encoded at the third and/or 
fourth position in the peptide (D), suggesting that this feature may be an important part of 







Fig. S13. Saturation mutagenesis defines the degrons recognized by Cul2ZYG11B and 
Cul2ZER1.  
(A-C) Saturation mutagenesis of the N-terminal peptides derived from the (A) ZNF701, 
(B) HBG2 and (C) DDX19B genes in different genetic backgrounds. A Ub-peptide-GPS 
library was generated in which each of the first ten residues of the peptides were mutated 
to all possible amino acids; the library was then expressed in either wild-type, ZYG11B 
mutant or ZER1 mutant HEK-293T cells and the stability of each mutant was measured 
by FACS followed by Illumina sequencing. For the left three columns, the color scale 
reflects the raw PSI measurement for each peptide-GFP fusion and thus the greater the 
intensity of the red color, the greater the stabilizing effect of the mutation. For the 
rightmost column, the color scale reflects the difference between the PSI in ZYG11B 
mutant cells versus ZER1 mutant cells and thus a dark red color indicates mutations 
which prevent recognition by ZER1 but not by ZYG11B, while a dark blue color 
indicates mutations which permit recognition by ZER1 but not by ZYG11B. In all plots, 
the column labeled ‘add’ represents the addition of an amino acid between the initiator 












Fig. S14. Caspase cleavage generates N-terminal glycine degrons targeted by 
ZYG11B and ZER1.  
(A) Caspase cleavage sites represent a source of N-terminal glycine degrons. Profiles for 
four example substrates from the Ub-GPS screen with the caspase cleavage product 
library are shown, illustrating the distribution of Illumina sequencing reads across the six 
bins. The amino acids around the caspase site are indicated, with the position of cleavage 
indicated by an arrow. 
(B) Destabilization via N-terminal glycine degrons following proteolytic cleavage. The 
full-length ORFs encoding the indicated proteins were modified such that their annotated 
caspase cleavage site was replace with a TEV protease cleavage site. Upon TEV 
expression, as monitored by the co-expression of BFP (top row), the stability of the 
downstream cleavage product decreased in wild-type cells (bottom row, left), but not in 
combined ZYG11B/ZER1 mutant cells (bottom row, right).  
(C) N-terminal glycine and serine have contrasting effects on protein stability. The letter-
value boxplots depict the distribution of stability scores for all peptide-GFP fusions in the 
caspase cleavage site library commencing with either an N-terminal glycine (red) or 










Fig. S15. A failure of N-myristoylation exposes N-terminal glycine degrons targeted 
by ZYG11B and ZER1.  
(A) GPS screen profiles for the six peptides selected for individual validation; concordant 
destabilization was observed in all three NMT1/2 mutant clones.  
(B) Ablation of NMT1/2 impairs the membrane localization of example peptide-GFP 
substrates. The first 24 amino acids from the indicated proteins were expressed as N-
terminal fusions to GFP in HEK-293T cells and their localization assessed by 
fluorescence microscopy. The membrane localization apparent in wild-type cells (top 
row) is abolished in NMT1/2 mutant clone #3 (middle row), and the abundance of the 
peptide-GFP fusions in the NMT1/2 mutant clones is increased upon mutation of 
ZYG11B and ZER1. 
(C) Small molecule NMT inhibition further destabilizes example peptide-GFP substrates. 
Treatment with the NMT1/2 inhibitor IMP-1088 (dotted lines) decreases the stability of 
the peptide-GFP substrates, both in wild-type cells (gray histograms) and NMT1/2 








Additional Data table S1 (separate file) 
N-terminome GPS screen data in wild-type cells. 
Additional Data table S2 (separate file) 
Computational prediction of N-terminal degrons. 
Additional Data table S3 (separate file) 
N-terminome GPS screen data in different genetic backgrounds. 
Additional Data table S4 (separate file) 
Saturation mutagenesis data. 
Additional Data table S5 (separate file) 
CRISPR screen data. 
Additional Data table S6 (separate file) 
Caspase cleavage product GPS screen data. 
 
 
 
